APA (7th ed.) Citation

Kuzuya, T., Muto, H., Tachi, Y., Komura, G., Nakano, T., Tanaka, H., . . . Ohno, E. (2026). Efficacy of Second-Line Lenvatinib After Atezolizumab–Bevacizumab and Durvalumab–Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response. Cancers, 18(13), 2095. https://doi.org/10.3390/cancers18132095

Chicago Style (17th ed.) Citation

Kuzuya, Teiji, et al. "Efficacy of Second-Line Lenvatinib After Atezolizumab–Bevacizumab and Durvalumab–Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response." Cancers 18, no. 13 (2026): 2095. https://doi.org/10.3390/cancers18132095.

MLA (9th ed.) Citation

Kuzuya, Teiji, et al. "Efficacy of Second-Line Lenvatinib After Atezolizumab–Bevacizumab and Durvalumab–Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response." Cancers, vol. 18, no. 13, 2026, p. 2095, https://doi.org/10.3390/cancers18132095.